All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What new technologies are available in the field of CAR T manufacturing?
Bookmark this article
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Bruce Levine from the University of Pennsylvania, Philadelphia, US, discusses what new technologies are available in the field of CAR T manufacturing.
Bruce Levine talks about novel technologies in CAR T cell manufacturing that will increase the effectiveness of CAR T such as the incorporation of biomarkers as a prognostic factor for response. In addition to this, he explains strategies such as shorting the process of CAR T manufacturing to reduce overall costs.
What new technologies are available in the field of CAR T manufacturing?
More about...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox